ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS
The data from a number of clinical trials investigating a once-yearly infusion of5 mg zoledronic acidshow a marked efficacy of this intervention in the treatment of primary and secondary osteoporosis with a combination of fracture risk reduction and prevention of bone loss at key skeletal sites. Rec...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
S Yu Vorotnikova [verfasserIn] E A Pigarova [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch ; Russisch |
| Erschienen: |
2016 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Остеопороз и остеопатии - Endocrinology Research Centre, 2018, 19(2016), 3, Seite 23-27 |
|---|---|
| Übergeordnetes Werk: |
volume:19 ; year:2016 ; number:3 ; pages:23-27 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.14341/osteo2016323-27 |
|---|
| Katalog-ID: |
DOAJ005017742 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ005017742 | ||
| 003 | DE-627 | ||
| 005 | 20230502123649.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14341/osteo2016323-27 |2 doi | |
| 035 | |a (DE-627)DOAJ005017742 | ||
| 035 | |a (DE-599)DOAJ3765946a1cdb49fbb715fcd71cdbeb3e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a rus | ||
| 050 | 0 | |a RZ301-397.5 | |
| 100 | 0 | |a S Yu Vorotnikova |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The data from a number of clinical trials investigating a once-yearly infusion of5 mg zoledronic acidshow a marked efficacy of this intervention in the treatment of primary and secondary osteoporosis with a combination of fracture risk reduction and prevention of bone loss at key skeletal sites. Recent research studies demonstrate beneficial features of original and generic zoledronic acid for treatment of patients with osteogenesis imperfecta, primary hyperparathyroidism, Paget’s disease of bone,vertebroplasty and dental implantation. | ||
| 650 | 4 | |a остеопороз | |
| 650 | 4 | |a золедроновая кислота | |
| 650 | 4 | |a бисфосфонаты | |
| 650 | 4 | |a переломы | |
| 653 | 0 | |a Osteopathy | |
| 700 | 0 | |a E A Pigarova |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Остеопороз и остеопатии |d Endocrinology Research Centre, 2018 |g 19(2016), 3, Seite 23-27 |w (DE-627)1760648779 |x 23110716 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2016 |g number:3 |g pages:23-27 |
| 856 | 4 | 0 | |u https://doi.org/10.14341/osteo2016323-27 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/3765946a1cdb49fbb715fcd71cdbeb3e |z kostenfrei |
| 856 | 4 | 0 | |u https://endojournals.ru/index.php/osteo/article/view/9203 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2072-2680 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2311-0716 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2016 |e 3 |h 23-27 | ||
| author_variant |
s y v syv e a p eap |
|---|---|
| matchkey_str |
article:23110716:2016----::oernccdnhtetetfseprssnoh |
| hierarchy_sort_str |
2016 |
| callnumber-subject-code |
RZ |
| publishDate |
2016 |
| allfields |
10.14341/osteo2016323-27 doi (DE-627)DOAJ005017742 (DE-599)DOAJ3765946a1cdb49fbb715fcd71cdbeb3e DE-627 ger DE-627 rakwb eng rus RZ301-397.5 S Yu Vorotnikova verfasserin aut ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The data from a number of clinical trials investigating a once-yearly infusion of5 mg zoledronic acidshow a marked efficacy of this intervention in the treatment of primary and secondary osteoporosis with a combination of fracture risk reduction and prevention of bone loss at key skeletal sites. Recent research studies demonstrate beneficial features of original and generic zoledronic acid for treatment of patients with osteogenesis imperfecta, primary hyperparathyroidism, Paget’s disease of bone,vertebroplasty and dental implantation. остеопороз золедроновая кислота бисфосфонаты переломы Osteopathy E A Pigarova verfasserin aut In Остеопороз и остеопатии Endocrinology Research Centre, 2018 19(2016), 3, Seite 23-27 (DE-627)1760648779 23110716 nnns volume:19 year:2016 number:3 pages:23-27 https://doi.org/10.14341/osteo2016323-27 kostenfrei https://doaj.org/article/3765946a1cdb49fbb715fcd71cdbeb3e kostenfrei https://endojournals.ru/index.php/osteo/article/view/9203 kostenfrei https://doaj.org/toc/2072-2680 Journal toc kostenfrei https://doaj.org/toc/2311-0716 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 19 2016 3 23-27 |
| spelling |
10.14341/osteo2016323-27 doi (DE-627)DOAJ005017742 (DE-599)DOAJ3765946a1cdb49fbb715fcd71cdbeb3e DE-627 ger DE-627 rakwb eng rus RZ301-397.5 S Yu Vorotnikova verfasserin aut ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The data from a number of clinical trials investigating a once-yearly infusion of5 mg zoledronic acidshow a marked efficacy of this intervention in the treatment of primary and secondary osteoporosis with a combination of fracture risk reduction and prevention of bone loss at key skeletal sites. Recent research studies demonstrate beneficial features of original and generic zoledronic acid for treatment of patients with osteogenesis imperfecta, primary hyperparathyroidism, Paget’s disease of bone,vertebroplasty and dental implantation. остеопороз золедроновая кислота бисфосфонаты переломы Osteopathy E A Pigarova verfasserin aut In Остеопороз и остеопатии Endocrinology Research Centre, 2018 19(2016), 3, Seite 23-27 (DE-627)1760648779 23110716 nnns volume:19 year:2016 number:3 pages:23-27 https://doi.org/10.14341/osteo2016323-27 kostenfrei https://doaj.org/article/3765946a1cdb49fbb715fcd71cdbeb3e kostenfrei https://endojournals.ru/index.php/osteo/article/view/9203 kostenfrei https://doaj.org/toc/2072-2680 Journal toc kostenfrei https://doaj.org/toc/2311-0716 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 19 2016 3 23-27 |
| allfields_unstemmed |
10.14341/osteo2016323-27 doi (DE-627)DOAJ005017742 (DE-599)DOAJ3765946a1cdb49fbb715fcd71cdbeb3e DE-627 ger DE-627 rakwb eng rus RZ301-397.5 S Yu Vorotnikova verfasserin aut ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The data from a number of clinical trials investigating a once-yearly infusion of5 mg zoledronic acidshow a marked efficacy of this intervention in the treatment of primary and secondary osteoporosis with a combination of fracture risk reduction and prevention of bone loss at key skeletal sites. Recent research studies demonstrate beneficial features of original and generic zoledronic acid for treatment of patients with osteogenesis imperfecta, primary hyperparathyroidism, Paget’s disease of bone,vertebroplasty and dental implantation. остеопороз золедроновая кислота бисфосфонаты переломы Osteopathy E A Pigarova verfasserin aut In Остеопороз и остеопатии Endocrinology Research Centre, 2018 19(2016), 3, Seite 23-27 (DE-627)1760648779 23110716 nnns volume:19 year:2016 number:3 pages:23-27 https://doi.org/10.14341/osteo2016323-27 kostenfrei https://doaj.org/article/3765946a1cdb49fbb715fcd71cdbeb3e kostenfrei https://endojournals.ru/index.php/osteo/article/view/9203 kostenfrei https://doaj.org/toc/2072-2680 Journal toc kostenfrei https://doaj.org/toc/2311-0716 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 19 2016 3 23-27 |
| allfieldsGer |
10.14341/osteo2016323-27 doi (DE-627)DOAJ005017742 (DE-599)DOAJ3765946a1cdb49fbb715fcd71cdbeb3e DE-627 ger DE-627 rakwb eng rus RZ301-397.5 S Yu Vorotnikova verfasserin aut ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The data from a number of clinical trials investigating a once-yearly infusion of5 mg zoledronic acidshow a marked efficacy of this intervention in the treatment of primary and secondary osteoporosis with a combination of fracture risk reduction and prevention of bone loss at key skeletal sites. Recent research studies demonstrate beneficial features of original and generic zoledronic acid for treatment of patients with osteogenesis imperfecta, primary hyperparathyroidism, Paget’s disease of bone,vertebroplasty and dental implantation. остеопороз золедроновая кислота бисфосфонаты переломы Osteopathy E A Pigarova verfasserin aut In Остеопороз и остеопатии Endocrinology Research Centre, 2018 19(2016), 3, Seite 23-27 (DE-627)1760648779 23110716 nnns volume:19 year:2016 number:3 pages:23-27 https://doi.org/10.14341/osteo2016323-27 kostenfrei https://doaj.org/article/3765946a1cdb49fbb715fcd71cdbeb3e kostenfrei https://endojournals.ru/index.php/osteo/article/view/9203 kostenfrei https://doaj.org/toc/2072-2680 Journal toc kostenfrei https://doaj.org/toc/2311-0716 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 19 2016 3 23-27 |
| allfieldsSound |
10.14341/osteo2016323-27 doi (DE-627)DOAJ005017742 (DE-599)DOAJ3765946a1cdb49fbb715fcd71cdbeb3e DE-627 ger DE-627 rakwb eng rus RZ301-397.5 S Yu Vorotnikova verfasserin aut ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The data from a number of clinical trials investigating a once-yearly infusion of5 mg zoledronic acidshow a marked efficacy of this intervention in the treatment of primary and secondary osteoporosis with a combination of fracture risk reduction and prevention of bone loss at key skeletal sites. Recent research studies demonstrate beneficial features of original and generic zoledronic acid for treatment of patients with osteogenesis imperfecta, primary hyperparathyroidism, Paget’s disease of bone,vertebroplasty and dental implantation. остеопороз золедроновая кислота бисфосфонаты переломы Osteopathy E A Pigarova verfasserin aut In Остеопороз и остеопатии Endocrinology Research Centre, 2018 19(2016), 3, Seite 23-27 (DE-627)1760648779 23110716 nnns volume:19 year:2016 number:3 pages:23-27 https://doi.org/10.14341/osteo2016323-27 kostenfrei https://doaj.org/article/3765946a1cdb49fbb715fcd71cdbeb3e kostenfrei https://endojournals.ru/index.php/osteo/article/view/9203 kostenfrei https://doaj.org/toc/2072-2680 Journal toc kostenfrei https://doaj.org/toc/2311-0716 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 19 2016 3 23-27 |
| language |
English Russian |
| source |
In Остеопороз и остеопатии 19(2016), 3, Seite 23-27 volume:19 year:2016 number:3 pages:23-27 |
| sourceStr |
In Остеопороз и остеопатии 19(2016), 3, Seite 23-27 volume:19 year:2016 number:3 pages:23-27 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
остеопороз золедроновая кислота бисфосфонаты переломы Osteopathy |
| isfreeaccess_bool |
true |
| container_title |
Остеопороз и остеопатии |
| authorswithroles_txt_mv |
S Yu Vorotnikova @@aut@@ E A Pigarova @@aut@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
1760648779 |
| id |
DOAJ005017742 |
| language_de |
englisch russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ005017742</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502123649.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14341/osteo2016323-27</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ005017742</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3765946a1cdb49fbb715fcd71cdbeb3e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RZ301-397.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">S Yu Vorotnikova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The data from a number of clinical trials investigating a once-yearly infusion of5 mg zoledronic acidshow a marked efficacy of this intervention in the treatment of primary and secondary osteoporosis with a combination of fracture risk reduction and prevention of bone loss at key skeletal sites. Recent research studies demonstrate beneficial features of original and generic zoledronic acid for treatment of patients with osteogenesis imperfecta, primary hyperparathyroidism, Paget’s disease of bone,vertebroplasty and dental implantation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">остеопороз</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">золедроновая кислота</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">бисфосфонаты</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">переломы</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Osteopathy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E A Pigarova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Остеопороз и остеопатии</subfield><subfield code="d">Endocrinology Research Centre, 2018</subfield><subfield code="g">19(2016), 3, Seite 23-27</subfield><subfield code="w">(DE-627)1760648779</subfield><subfield code="x">23110716</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:23-27</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14341/osteo2016323-27</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3765946a1cdb49fbb715fcd71cdbeb3e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://endojournals.ru/index.php/osteo/article/view/9203</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-2680</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2311-0716</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2016</subfield><subfield code="e">3</subfield><subfield code="h">23-27</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
S Yu Vorotnikova |
| spellingShingle |
S Yu Vorotnikova misc RZ301-397.5 misc остеопороз misc золедроновая кислота misc бисфосфонаты misc переломы misc Osteopathy ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS |
| authorStr |
S Yu Vorotnikova |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760648779 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RZ301-397 |
| illustrated |
Not Illustrated |
| issn |
23110716 |
| topic_title |
RZ301-397.5 ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS остеопороз золедроновая кислота бисфосфонаты переломы |
| topic |
misc RZ301-397.5 misc остеопороз misc золедроновая кислота misc бисфосфонаты misc переломы misc Osteopathy |
| topic_unstemmed |
misc RZ301-397.5 misc остеопороз misc золедроновая кислота misc бисфосфонаты misc переломы misc Osteopathy |
| topic_browse |
misc RZ301-397.5 misc остеопороз misc золедроновая кислота misc бисфосфонаты misc переломы misc Osteopathy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Остеопороз и остеопатии |
| hierarchy_parent_id |
1760648779 |
| hierarchy_top_title |
Остеопороз и остеопатии |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760648779 |
| title |
ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS |
| ctrlnum |
(DE-627)DOAJ005017742 (DE-599)DOAJ3765946a1cdb49fbb715fcd71cdbeb3e |
| title_full |
ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS |
| author_sort |
S Yu Vorotnikova |
| journal |
Остеопороз и остеопатии |
| journalStr |
Остеопороз и остеопатии |
| callnumber-first-code |
R |
| lang_code |
eng rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
txt |
| container_start_page |
23 |
| author_browse |
S Yu Vorotnikova E A Pigarova |
| container_volume |
19 |
| class |
RZ301-397.5 |
| format_se |
Elektronische Aufsätze |
| author-letter |
S Yu Vorotnikova |
| doi_str_mv |
10.14341/osteo2016323-27 |
| author2-role |
verfasserin |
| title_sort |
zoledronic acid in the treatment of osteoporosis and other skeletal disorders |
| callnumber |
RZ301-397.5 |
| title_auth |
ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS |
| abstract |
The data from a number of clinical trials investigating a once-yearly infusion of5 mg zoledronic acidshow a marked efficacy of this intervention in the treatment of primary and secondary osteoporosis with a combination of fracture risk reduction and prevention of bone loss at key skeletal sites. Recent research studies demonstrate beneficial features of original and generic zoledronic acid for treatment of patients with osteogenesis imperfecta, primary hyperparathyroidism, Paget’s disease of bone,vertebroplasty and dental implantation. |
| abstractGer |
The data from a number of clinical trials investigating a once-yearly infusion of5 mg zoledronic acidshow a marked efficacy of this intervention in the treatment of primary and secondary osteoporosis with a combination of fracture risk reduction and prevention of bone loss at key skeletal sites. Recent research studies demonstrate beneficial features of original and generic zoledronic acid for treatment of patients with osteogenesis imperfecta, primary hyperparathyroidism, Paget’s disease of bone,vertebroplasty and dental implantation. |
| abstract_unstemmed |
The data from a number of clinical trials investigating a once-yearly infusion of5 mg zoledronic acidshow a marked efficacy of this intervention in the treatment of primary and secondary osteoporosis with a combination of fracture risk reduction and prevention of bone loss at key skeletal sites. Recent research studies demonstrate beneficial features of original and generic zoledronic acid for treatment of patients with osteogenesis imperfecta, primary hyperparathyroidism, Paget’s disease of bone,vertebroplasty and dental implantation. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA |
| container_issue |
3 |
| title_short |
ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS |
| url |
https://doi.org/10.14341/osteo2016323-27 https://doaj.org/article/3765946a1cdb49fbb715fcd71cdbeb3e https://endojournals.ru/index.php/osteo/article/view/9203 https://doaj.org/toc/2072-2680 https://doaj.org/toc/2311-0716 |
| remote_bool |
true |
| author2 |
E A Pigarova |
| author2Str |
E A Pigarova |
| ppnlink |
1760648779 |
| callnumber-subject |
RZ - Other Systems of Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.14341/osteo2016323-27 |
| callnumber-a |
RZ301-397.5 |
| up_date |
2024-07-04T02:02:20.827Z |
| _version_ |
1803612104506212352 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ005017742</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502123649.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14341/osteo2016323-27</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ005017742</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3765946a1cdb49fbb715fcd71cdbeb3e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RZ301-397.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">S Yu Vorotnikova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The data from a number of clinical trials investigating a once-yearly infusion of5 mg zoledronic acidshow a marked efficacy of this intervention in the treatment of primary and secondary osteoporosis with a combination of fracture risk reduction and prevention of bone loss at key skeletal sites. Recent research studies demonstrate beneficial features of original and generic zoledronic acid for treatment of patients with osteogenesis imperfecta, primary hyperparathyroidism, Paget’s disease of bone,vertebroplasty and dental implantation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">остеопороз</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">золедроновая кислота</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">бисфосфонаты</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">переломы</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Osteopathy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E A Pigarova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Остеопороз и остеопатии</subfield><subfield code="d">Endocrinology Research Centre, 2018</subfield><subfield code="g">19(2016), 3, Seite 23-27</subfield><subfield code="w">(DE-627)1760648779</subfield><subfield code="x">23110716</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:23-27</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14341/osteo2016323-27</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3765946a1cdb49fbb715fcd71cdbeb3e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://endojournals.ru/index.php/osteo/article/view/9203</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-2680</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2311-0716</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2016</subfield><subfield code="e">3</subfield><subfield code="h">23-27</subfield></datafield></record></collection>
|
| score |
7.400996 |